Donepezil therapy in clinical practice: a randomized crossover study
- PMID: 10634454
- DOI: 10.1001/archneur.57.1.94
Donepezil therapy in clinical practice: a randomized crossover study
Abstract
Objective: To determine the efficacy of donepezil hydrochloride for the treatment of Alzheimer disease in patients drawn from clinical practice.
Design: Two-center, randomized, placebo-controlled, double-masked crossover study.
Setting: Memory disorders units at Massachusetts General and Brigham and Women's hospitals, Boston.
Patients: Sixty individuals (30 men and 30 women; mean +/- SD age, 75.0+/-9.5 years) with probable Alzheimer disease and scores of 20 or less on the information-memory-concentration subscale of the Blessed Dementia Scale.
Interventions: Placebo wash-in, followed in randomized sequence by (1) donepezil hydrochloride therapy, 5 mg/d, for 6 weeks, followed by placebo washout for 6 weeks and (2) placebo treatment for 6 weeks.
Primary outcome measure: Change in Alzheimer's Disease Assessment Scale cognitive subscale scores from the beginning to the end of the two 6-week treatment periods.
Results: Among patients completing treatment and testing for both periods (n = 48), subscale scores improved (mean +/- SEM) 2.17+/-0.98 points (95% confidence interval, 0.20-4.10 points) during donepezil therapy relative to placebo therapy (P = .04). Scores returned toward baseline within 3 weeks of drug washout. There was no associated change in caregiver-rated global impression (donepezil vs placebo: proportion improved, 0.24 vs 0.22; proportion worsened, 0.27 vs 0.35; P = .34) or on specific tests of explicit memory or verbal fluency. Contrary to studies with tacrine, the presence of the apolipoprotein E epsilon4 allele did not predict donepezil treatment failure. Most common adverse events related to donepezil therapy were nausea (5 patients), diarrhea (3 patients), and agitation (3 patients). Serious events possibly related to drug use were seizure, pancreatitis, and syncope (1 patient each).
Conclusion: This independent confirmation of data from phase 3 trials suggests that donepezil therapy modestly improves cognition in patients with Alzheimer disease who are encountered in clinical practice.
Comment in
-
Donepezil in the treatment of Alzheimer disease.Arch Neurol. 2000 Sep;57(9):1380. Arch Neurol. 2000. PMID: 10987910 No abstract available.
Similar articles
-
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. Epub 2009 Jan 28. Neurology. 2009. PMID: 19176895 Clinical Trial.
-
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.Int J Geriatr Psychiatry. 2004 Jul;19(7):624-33. doi: 10.1002/gps.1133. Int J Geriatr Psychiatry. 2004. PMID: 15254918 Review.
-
Donepezil for vascular cognitive impairment.Cochrane Database Syst Rev. 2004;(1):CD004395. doi: 10.1002/14651858.CD004395.pub2. Cochrane Database Syst Rev. 2004. PMID: 14974068 Review.
-
Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease.Arch Neurol. 2001 Mar;58(3):427-33. doi: 10.1001/archneur.58.3.427. Arch Neurol. 2001. PMID: 11255446 Clinical Trial.
-
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.Arch Intern Med. 1998 May 11;158(9):1021-31. doi: 10.1001/archinte.158.9.1021. Arch Intern Med. 1998. PMID: 9588436 Clinical Trial.
Cited by
-
Donepezil-induced bradycardia in a schizophrenic patient with comorbid neurocognitive disorder: a case report and review of the literature.J Med Case Rep. 2024 Mar 27;18(1):129. doi: 10.1186/s13256-024-04454-x. J Med Case Rep. 2024. PMID: 38532522 Free PMC article. Review.
-
The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.Naunyn Schmiedebergs Arch Pharmacol. 2022 May;395(5):535-546. doi: 10.1007/s00210-022-02209-3. Epub 2022 Feb 5. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35122115 Free PMC article.
-
Tiaobu Xinshen Recipe () Improved Mild Cognitive Impairment of Alzheimer's Disease Patients with Xin (Heart) and Shen (Kidney) Deficiency.Chin J Integr Med. 2020 Jan;26(1):54-58. doi: 10.1007/s11655-019-3073-z. Epub 2019 Nov 27. Chin J Integr Med. 2020. PMID: 31776960
-
Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease.Front Med (Lausanne). 2019 May 7;6:73. doi: 10.3389/fmed.2019.00073. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31134200 Free PMC article.
-
Donepezil for dementia due to Alzheimer's disease.Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical